Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03065218 : Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- > 18 years of age;

- Diagnosed with differentiated thyroid carcinoma;

- At least one prior I-131 therapy, which may be remnant ablation, adjuvant treatment,
and treatment of distant metastases,

- Elevated suppressed or stimulated thyroglobulin level (Tg) > 10 ng/ml with or WITHOUT
thyroglobulin antibodies ,

- All NEGATIVE standard diagnostic clinical imaging studies (SDCIS) = negative
ultrasound (US), diagnostic radioiodine scan (DRS), chest-x-ray (CXR), computer
tomography with or without contrast (CT), and 18F-Fluoro-deoxyglucose positron
emission computer tomography scan (18F-FDG PET) within the last 12 mos.

- If extensive diagnostic clinical imaging studies (EDCIS) of 18F-sodium fluoride
positron emission computer tomography scan (18F NaF PET) or 99mTc methylene
diphosphonate bone scan (99mTc MDP), AND brain CT or magnetic resonance (MR) are
performed, these are also negative.

Exclusion Criteria:

- < 18 years of age;

- Pregnant or breast feeding

- Any SDCIS or EDCIS that is positive and/or suggestive of recurrent and/or distant
metastases secondary to DTC. If a study is indeterminate, this will be forwarded to a
committee for review and resolution.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557